Stefan Müllner

Warburg-Glycomed GmbH is a biopharmaceutical company focused on the discovery and development of small molecule oncology drugs. The drug development platform of Warburg-Glycomed GmbH builds on profound know-how in cell energy metabolism, enzymology and signal transduction pathways of tumor cells and their translation into new classes of oncology drugs. The company was founded on October 1, 2007 and is headquartered in Erkrath, Germany.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Aventis SA develops pharmaceuticals and vaccines for preventative medicine. The company is located in Schiltigheim, France.

Protagen AG specializes in the development of novel diagnostic and companion diagnostic tests. Its products and services include GMP analyses, protein identification and analyses, proteome studies, UNIchip, clone and array, Bio-IT, Modiro as well as ProteinScape and Solver. The company was founded by Stefan Müllner, Helmut E. Meyer, Petra Weingarten and Martin Blüggel in 1997 and is headquartered in Dortmund, Germany.

fundamenta CAPITAL AG (fundamenta) is the financial services subsidiary of K + R Beteiligungs GmbH in Germany. Established in 1998, the firm supports biotech companies during the strategic preparation and carrying out of the second and third rounds of financing as well as with the acquisition and development of industry co-operations. They are headquartered in Bergisch Gladbach, Germany.